



Diabetes Technology Meeting (DTM) 2025

October 28-30, 2025; Burlingame, CA; Resource Hub – Draft

Welcome to our resource hub for the Diabetes Technology Meeting (DTM) 2025! This is a one-stop-shop for all your DTM 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.

Important Conference Information. We are so excited to see the return of DTM 2024 in-person this year, taking place at the San Francisco Airport Marriott Waterfront in Burlingame, CA October 28-30. Attendees will have access to all workshops taking place October 28th, and will receive a one-year subscription to [*Journal of Diabetes Science and Technology*](#).

Conference Recording Availability. DTM 2025 will not be available virtually, nor will sessions be available on-demand.

Table of Contents

[Useful Conference Links](#)

[Day-of Conference Reports](#)

[Top Highlights](#)

[Previous DTM Coverage on CCKB](#)

Useful Conference Links

1. [Conference Website](#)
2. [Conference Registration](#)
3. [Day-by-Day Conference Preview](#)
4. [Conference Program](#)

Day-of Conference Reports

1. [DTM 2025 Day #1 Highlights](#)
2. [DTM 2025 Day #2 Highlights](#)
3. [DTM 2025 Day #3 Highlights](#)

Top Highlights

1. [CGM or GLP-1 RAs](#): Lively debate discusses which option is more useful for diabetes treatment
2. [Not all AID algorithms are alike](#): A comparative look at modern systems
3. [Murphy’s Law in AID systems](#): Dr. Edelman on safe and smart AID use
4. [Redefining AID eligibility](#): Dr. Halis Akturk advocates for early and inclusive use of the technology
5. [Dr. Rich Bergenstal on the evolving role of the ambulatory glucose profile](#) and how to improve clinical relevance
6. [CGM for hospitals](#): Current limitations and future opportunities
7. [Diabetes data interoperability](#): iCoDE-2’s model for insulin data management and European perspectives on device regulation
8. [Presentation of CGM data](#): Actionable insights and new dimensions
9. [Newly published phase 3 trial demonstrates the role of AI](#) in diabetes prevention

10. [Integrating autonomous AI into diabetes care](#) to improve diabetic retinopathy screening in youth
11. [Fragmentation of care](#): Growing number of CGM and insulin delivery options complicates provider management
12. [Glycated albumin as a once-weekly home testing method](#) for non-insulin T2D management
13. [Dr. Rich Bergenstal emphasized the use of CGM metrics](#) and profiles to advance personalization of diabetes care
14. [AID without meal announcements](#): The efficacy and synergistic effects in people with T1D
15. [Making diabetes technology work for everyone](#): Impassioned panelists tackle access, education, and innovation
16. [Advancing diabetes care through technology](#): A tech-specific review of the ADA 2025 Standards of Care with Dr. Rita Kalyani
17. [Artificial Pancreas Award](#): Prof. Mohammed Al-Sofiani recognized for his work on AID systems for Ramadan fasting
18. [Diabetes Technology Leadership Award](#): Mr. Shahid Shah awarded honor for his work advancing AI infrastructure
19. [Escaping the “ceiling of improvement”](#): Neural networks for improved AID control
20. [Leaders across diabetes technology highlight AI’s](#) role in patient-centered diabetes care
21. [Abbott spotlights CGM impact in T2D](#) and looks ahead to real-time ketone monitoring
22. [TITR gains attention](#) across pediatric and adult diabetes care
23. [Advancing inpatient glycemic management](#) through CGM and automated insulin dosing algorithms
24. [Greater detail in fewer digits](#): Dr. Viral Shah on Glycemia Risk Index
25. [CGM offers great potential in monitoring](#) and diagnosis early-stage T1D
26. [Next-generation CGM innovations](#) focused on data integration and AI prediction
27. [FreeDM2 trial demonstrated clinically meaningfully A1c reduction](#) with FreeStyle Libre 3 in adults with T2D on basal insulin
28. [Diabetes and the environment](#): A bidirectional relationship
29. [Dr. Viral Shah challenges conventional definitions of “normal” glucose](#) in healthy individuals
30. [Diabetes Center Berne’s Open Innovation Challenge](#) brings passion and creativity to diabetes technology
31. [FDA’s Dr. Courtney Lias on new device authorizations](#), digital health frameworks, and evolving AI frameworks
32. [Multiple uses of GLP-1 RAs](#): Current and emerging indications
33. [C-peptide as a necessary and “more than sufficient” measurement](#) for approving disease-modifying treatments for T1D
34. [DTS Student Award](#): Virtual DCCT to estimate GRI as a predictor of complications
35. [twiist AID shows occlusion alarms](#) detect flow issues within 30 minutes and prompt timely user intervention
36. [History and progress of ultra-long-acting insulin](#): Overview on insulin icodec and efsitora alfa
37. [GLP-1 RAs and muscle atrophy](#): Emerging treatments and recommendations for addressing muscle loss

Previous DTM Coverage on CCKB

1. [DTM 2024 Resource Hub](#)
2. [DTM 2023 Resource Hub](#)
3. [DTM 2022 Resource Hub](#)
4. [DTM 2021 Resource Hub](#)
5. [DTM 2020 Full Report](#)
6. [DTM 2019 Full Report](#)

7. [DTM 2018 Full Report](#)
8. [DTM 2017 Full Report](#)
9. [DTM 2016 Full Report](#)
10. [DTM 2015 Full Report](#)